Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: PI Financial Corp
$81.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Mallinckrodt Inc announces completion of MNK-155 clinical trials


Thursday, 12 Dec 2013 08:45am EST 

Mallinckrodt Inc:Says it reported positive efficacy results in the Phase 3 clinical trial for MNK-155, an investigational extended-release oral formulation of hydrocodone and acetaminophen studied for the management of moderate to moderately severe acute pain where the use of an opioid analgesic is appropriate.Says MNK-155 met the primary endpoint in this study.Says Mallinckrodt also completed a series of other clinical trials evaluating pharmacokinetics, safety and abuse liability of MNK-155.Says these data, including the Phase 3 efficacy data, will be presented at a future medical meeting and will be submitted to the U.S. Food and Drug Administration (FDA) in a New Drug Application (NDA) for MNK-155.Says NDA is expected to be submitted in the second half of fiscal 2014. 

Company Quote

0.74
0.1 +15.63%
27 Mar 2015